Senzime AB reports recurring developments around its TetraGraph neuromuscular monitoring system, hospital contracting in the United States, and commercialization through integrated delivery networks and group purchasing organizations. Company updates also cover TetraCom connectivity, financial reports, margin and cash-flow commentary, and expansion of U.S. sales, clinical, and medical-affairs functions.
Governance-related announcements include annual general meeting notices and shareholder-program proposals, while operating updates focus on anesthesia data transmission, hospital procurement access, system installations, and recurring revenue tied to the installed base.
Senzime (SNZZF) reaffirmed its target of reaching positive cash flow within the fourth quarter of 2026 despite revenue growth challenges.
The company said it faces challenges in fully achieving its revenue growth targets for the year. Preliminary Q3 2026 figures indicate double-digit sales growth and further improved gross margins, alongside continued cost control and optimized working capital. These are preliminary indicators, not the full quarterly results.
Senzime identifies these operating and working-capital developments as drivers toward its positive cash flow target. The target remains a future goal rather than an achieved result. The full Q3 2026 report is scheduled for release on October 29, 2026.
Senzime (SNZZF) secured a SEK 35 million non-dilutive credit facility from institutional investors to support its operations and OEM expansion.
The facility replaces a previously communicated credit line without increasing total credit capacity. Investors include the Segulah and Crafoord groups. Senzime may draw cash in tranches and pays interest only on amounts drawn; the facility includes no warrants or other dilutive instruments. The company says improving gross margins, cost controls and available funds give it the capital needed to reach profitability while investing in its products and OEM programs.
A partnership with Philips Medical Systems announced in July 2026 aims to develop monitoring solutions for additional market segments, to be sold through Philips' organization. Commercialization depends on successful development, and Senzime has not provided Philips-specific forecasts for timing, volumes or revenue. It aims for OEM collaborations to generate more than 50 percent of long-term revenue; that ambition is not financial guidance.
Senzime (SNZZF) secured a contract with an eastern US multi-hospital academic health system for an initial deployment of 60 TetraGraph systems.
The systems will be used in operating rooms to monitor patients undergoing anesthesia. At expected utilization levels, the deployment is expected to cover approximately 10,000 patients annually using disposable TetraSens sensors. Senzime says the contract expands its US installed base and could lead to wider deployment across the hospital network.
TetraGraph is used in more than 750 hospitals and has monitored more than one million patients.
Senzime (OTCQX:SNZZF, STO:SEZI) announced that the U.S. Department of Veterans Affairs Strategic Acquisition Center has awarded an exclusive five-year national Non-Expendable Equipment contract for quantitative neuromuscular monitoring to TrillaMed, the authorized U.S. federal distributor of Senzime’s TetraGraph system.
The agreement, following a competitive national procurement, makes TetraGraph the only quantitative neuromuscular monitoring solution available through the VA Strategic Acquisition Center’s national contracting program. More than 170 VA hospitals and healthcare facilities gain streamlined access via pre-negotiated pricing and simplified procurement, which Senzime expects will significantly expand TetraGraph adoption across the VA healthcare system over the next five years.
Senzime (OTCQX:SNZZF) reported Q2 2026 net sales of TSEK 24,671, down 4% year-on-year, with U.S. sales decreasing 6% to TSEK 18,716 and international sales up 3% to TSEK 5,955. Currency-adjusted net sales fell 1%. Gross margin before depreciation improved to 65.7% from 61.8%, while operating costs declined to TSEK 34,201 from 40,207, reducing operating loss before depreciation to TSEK -17,267.
Results after financial items improved to TSEK -21,385 from -34,159, and EPS was SEK -0.14 versus -0.24. Cash and cash equivalents fell to TSEK 37,112 from 132,162. Sensor sales in local currencies grew 48% and now represent about 80% of revenue. Senzime highlighted a new long-term strategic partnership with Philips Medical Systems to co-develop products sold via Philips’ global network, additional FDA 510(k) clearance for TetraGraph, and Brazilian ANVISA approval. The company also reported 15% lower operating expenses, about 27% EBITDA improvement, 45% better cash flow, and nearly 6,000 TetraGraph systems shipped.
Senzime (OTCQX:SNZZF, STO:SEZI) has entered into a long-term development and commercialization agreement with Philips Electronics Nederland B.V. through Philips Hospital Patient Monitoring, a global provider of patient monitoring systems. The partnership will explore and develop future solutions that combine the companies’ proprietary technologies and target market segments that complement Senzime’s existing products and sales channels.
According to Senzime, any resulting solutions will be commercialized via Philips’ global organization, while being managed within Senzime alongside its current portfolio. The company stated that the agreement is expected to broaden its reach to tens of thousands of hospitals and create new revenue streams over the medium to long term. Senzime noted its monitoring solutions have already been used on more than one million patients and are currently sold directly in the United States and Germany and via distribution and license partners in over 30 additional countries.
Senzime (OTCQX:SNZZF, STO:SEZI) will present its second quarter 2026 report on July 16, 2026. The report is scheduled for publication at 08:00 am CEST, followed by a CEO webcast at 09:00 am CEST and a live Q&A at 10:00 am CEST.
Senzime (OTCQX:SNZZF) reported that its TetraGraph neuromuscular monitoring system received regulatory approval from Brazil’s health agency ANVISA, enabling sales in Brazil. The company has begun commercialization via exclusive local partner Vivelo and has already received a first order.
TetraGraph supports anesthesiologists by monitoring neuromuscular function during surgery.
Senzime (OTCQX:SNZZF) launched TetraAnalytics, a cloud-based data analytics platform that extends the TetraGraph neuromuscular monitoring system. The platform automates data analysis, tracks protocol and guideline alignment, uses the Train-of-Four Quality Indicator (TQi), and supports advanced visualization and remote analytics for perioperative care improvement.
Senzime will showcase TetraAnalytics, the next-generation TetraGraph system and the new TetraSens EMG sensor at Euroanaesthesia 2026 in Rotterdam and sponsor a lunch symposium on neuromuscular monitoring advances.
Senzime (OTCQX:SNZZF) reported progress in pediatric anesthesia, winning a new contract from a top-ranked pediatric hospital in the Eastern U.S. to equip all operating rooms with TetraGraph systems after competitive evaluation.
New pediatric research shows reduced respiratory complications and cost savings with quantitative neuromuscular monitoring.